These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells. Svensson E; Vidovic K; Lassen C; Richter J; Olofsson T; Fioretos T; Gullberg U Leukemia; 2007 Dec; 21(12):2485-94. PubMed ID: 17728783 [TBL] [Abstract][Full Text] [Related]
11. Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein. Elzinga BM; Nyhan MJ; Crowley LC; O'Donovan TR; Cahill MR; McKenna SL Am J Hematol; 2013 Jun; 88(6):455-62. PubMed ID: 23440701 [TBL] [Abstract][Full Text] [Related]
12. Global effects of BCR/ABL and TEL/PDGFRbeta expression on the proteome and phosphoproteome: identification of the Rho pathway as a target of BCR/ABL. Unwin RD; Sternberg DW; Lu Y; Pierce A; Gilliland DG; Whetton AD J Biol Chem; 2005 Feb; 280(8):6316-26. PubMed ID: 15569670 [TBL] [Abstract][Full Text] [Related]
13. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. Oetzel C; Jonuleit T; Götz A; van der Kuip H; Michels H; Duyster J; Hallek M; Aulitzky WE Clin Cancer Res; 2000 May; 6(5):1958-68. PubMed ID: 10815921 [TBL] [Abstract][Full Text] [Related]
14. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377 [TBL] [Abstract][Full Text] [Related]
15. Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines. Barnes DJ; De S; van Hensbergen P; Moravcsik E; Melo JV Leukemia; 2007 Mar; 21(3):421-6. PubMed ID: 17252018 [TBL] [Abstract][Full Text] [Related]
16. Erythropoietin promotes resistance against the Abl tyrosine kinase inhibitor imatinib (STI571) in K562 human leukemia cells. Kirschner KM; Baltensperger K Mol Cancer Res; 2003 Nov; 1(13):970-80. PubMed ID: 14638869 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. von Bubnoff N; Veach DR; Miller WT; Li W; Sänger J; Peschel C; Bornmann WG; Clarkson B; Duyster J Cancer Res; 2003 Oct; 63(19):6395-404. PubMed ID: 14559829 [TBL] [Abstract][Full Text] [Related]
18. Mechanisms of transformation by the BCR/ABL oncogene. Sattler M; Griffin JD Int J Hematol; 2001 Apr; 73(3):278-91. PubMed ID: 11345193 [TBL] [Abstract][Full Text] [Related]
19. Reduced focal adhesion kinase and paxillin phosphorylation in BCR-ABL-transfected cells. Cheng K; Kurzrock R; Qiu X; Estrov Z; Ku S; Dulski KM; Wang JY; Talpaz M Cancer; 2002 Jul; 95(2):440-50. PubMed ID: 12124845 [TBL] [Abstract][Full Text] [Related]
20. Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance. Kurzrock R; Talpaz M; Li L; Estrov Z Leuk Lymphoma; 2006 Aug; 47(8):1651-64. PubMed ID: 16966279 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]